Arecor Therapeutics Plc · LSE:AREC
Arecor Therapeutics — H1 2024 Earnings Presentation
23 slides from Arecor Therapeutics's earnings presentation, Sep 26, 2024
Slide 1: Advancing today's therapies to enable healthier lives
Advancing today’s therapies to enable healthier lives Interim results for the six months ended 30 June 2024 26th September 2024 www.arecor.com
Slide 2: Legal notice
Legal notice This Presentation does not constitute, or form part of, nor is it intended to communicate, any offer, invitation, inducement or recommendation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in the Company in any jurisdiction nor shall it, or
Slide 3: Building value through better patient care
Building value through better patient care Developing enhanced therapeutics that address areas of high unmet need in high value markets ArestatTM Platform Technology Diabetes & Obesity Specialty hospital Revenue generating partnerships In-house Technology In-house Commercial Technology Licensed prop
Slide 4: A broad portfolio of de-risked development and commercial products
A broad portfolio of de-risked development and commercial products Balanced portfolio of commercial and development assets targeting large market opportunities Current Product Area Research Preclinical Phase I Phase II Phase III Est launch1 market size AT278 Diabetes 2030 ~$6.4bn2 In-House Proprieta
Slide 5: Operational highlights (including post-period events)
Operational highlights (including post-period events) Building towards a significant self-sustaining biopharmaceutical company Advanced and expanded diabetes & obesity pipeline • AT278 – Demonstrated superiority in a Phase I clinical study in T2DM’s with high BMI • Oral GLP-1 – programme initiated a
Slide 6: AT278 demonstrates superiority
AT278 demonstrates superiority compared with best insulins available today
Slide 7: The profile of AT278 addresses key unmet needs and expanded applications
The profile of AT278 addresses key unmet needs and expanded applications AT278 products provide additional treatment options without directly competing with existing products Insulin pump therapy today The future • Insulin pumps/automated insulin delivery (AID) systems • Lowering burden whilst impro
Slide 8: AT278 Phase I clinical trial in overweight and obese T2DM's study overview
AT278 Phase I clinical trial in overweight and obese T2DM’s study overview Potential to become gold standard insulin for people with diabetes with high daily insulin needs Treatment Treatment Treatment Follow-up period 1 period 2 period 3 AT278 AT278 Single s.c. dose of 0.5 Single s.c. dose of 0.5 U
Slide 9: AT278 demonstrated PK superiority compared with NovoRapid & Humulin-R U500
AT278 (500U/mL) demonstrated PK superiority compared with NovoRapid® (100U/mL) & Humulin-R U500 in T2D patients with high BMI Potential to be insulin of choice for high insulin users and catalyse next generation of smaller, longer wear pumps AT278 showed superiority for onset of appearance and insul
Slide 10: AT278 demonstrated PD superiority compared with NovoRapid & Humulin-R U500
AT278 (500U/mL) demonstrated PD superiority compared with NovoRapid® (100U/mL) & Humulin-R U500 in T2D patients with high BMI AT278 showed superiority for for early insulin action with accelerated onset of glucose-lowering effect (PD) during 60 mins after dosing compared with NovoRapid® and a shorte
Slide 11: AT278 demonstrated superior PK/PD compared with NovoRapid
AT278 demonstrated superior PK/PD compared with NovoRapid® with clear potential to be the only insulin to catalyse development of next generation insulin pump therapy AT278 U500 Serum insulin aspart (µU/mL) 200 PK PD AT278 U500 Glucose infusion rate (mg/kg/min) 7 IAsp U100 IAsp U100 6 160 5 120 4 80
Slide 12: Summary of AT278-104 Phase 1 clinical results
Summary of AT278-104 Phase 1 clinical results Demonstrating superiority compared with NovoRapid® and Humulin-R U500® • AT278 demonstrates significantly superior accelerated PK/PD profile compared to NovoRapid® and Humulin® R U-500 in people with Type 2 Diabetes and high BMI • Confirms previous trial
Slide 13: AT278 development to end Phase 1/2 3-day insulin pump study
AT278 development to end Phase 1/2 3-day insulin pump study Continuing to explore non-dilutive funding options for AT278 End 2024 End 2025 Why is this study important: ----------------------- ----------------------- • Strategic co-development partnering discussions on-going with device co AT278-104
Slide 14: Oral delivery of peptides
Oral delivery of peptides : ? ) )
Slide 15: Significant additional upside opportunity in oral peptide delivery
Significant additional upside opportunity in oral peptide delivery Development of oral GLP and additional therapies offering alternative treatment options in large markets Oral delivery PoC GLP-1 • Collaboration with TRx Biosciences’ combining delivery technologies to develop enhanced oral GLP-1 • P
Slide 16: Tetris Pharma Ogluo
» Tetris Pharma Ogluo® ( (
Slide 17: Ogluo - Focus on key markets to drive growth
Ogluo® - Focus on key markets to drive growth Implementing targeted awareness campaign to drive demand 18%market UK glucagon UK RTU glucagon market total value of ~£18m 9% • Glucagen rescue kit (lyophilised for reconstitution) is Ogluo®’s only competitor • Ogluo® reached ~9% market share by unit in
Slide 18: Ogluo key milestones
Ogluo® key milestones Focus through 2024 and 2025 to drive awareness, demand and revenue growth for Ogluo® and ensure robust supply chain Priorities to drive growth • Growth in home UK market • Focus on approval across 25 ICS key formularies that account for 80% of glucagon prescriptions • Significa
Slide 19: Financials
mlatelaleteles
Slide 20: 2024 H1 financial highlights
2024 H1 financial highlights Key financials Continued Continued increasing increasing revenues with • Revenue increased by 20% to £2.0m (H1 2023: £1.67m) revenues strong with strong 2H 2H anticipated • Total income £2.03m (H1 2023: £2.33m) anticipated • Investment in R&D of £2.09m (H1 2023: £2.86m)
Slide 21: Key financials
Key financials Focus on delivering consistent year-on-year revenue growth £’m H1 2024 H1 2023 Diversified revenue mix • Growing royalty revenue from w/w AT220 Formulation development 0.38 0.34 license agreement • Tetris Pharma product sales increased Milestone - 0.1 despite tempering of Ogluo® stock
Slide 22: A series of significant upcoming milestones
A series of significant upcoming milestones Multiple opportunities for significant value creation • Continue to explore strategic co-development and non-dilutive funding to progress 3-day insulin pump study • Major value driver for AT278 increasing potential and value of future deal making • Growing
Slide 23: Thank you
Contact Sarah Howell, CEO sarah.howell@arecor.com www.arecor.com Thank you